MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MTVA MetaVia Inc

Post-Mkt 07-24 17:45:51 EDT

1.48

-0.03

-1.99%

盘后1.50

+0.02+1.35%

16:45 EDT

High1.54	Low1.46	Vol69.55K
Open1.47	D1 Closing1.51	Amplitude5.24%
Mkt Cap7.64M	Tradable Cap5.00M	Total Shares5.16M
T/O103.81K	T/O Rate2.06%	Tradable Shares3.38M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":1.48,"timestamp":1784923200000,"preClose":1.51,"halted":0,"volume":69551,"hourTrading":{"tag":"盘后","latestPrice":1.5,"preClose":1.48,"latestTime":"16:45 EDT","volume":619,"amount":915.0800181,"timestamp":1784925945176,"change":0.02,"changeRate":0.013514,"amplitude":0.02027},"delay":0,"changeRate":-0.01986754966887419,"floatShares":3381500,"shares":5164400,"eps":-2.541,"marketStatus":"Post-Mkt","change":-0.03,"latestTime":"07-24 17:45:51 EDT","open":1.47,"high":1.5391,"low":1.46,"amount":103810.9393023,"amplitude":0.052384,"askPrice":1.5,"askSize":100,"bidPrice":1.44,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-2.541,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1784937600000},"marketStatusCode":4,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":1.51,"preHourTrading":{"tag":"盘前","latestPrice":1.54,"preClose":1.51,"latestTime":"08:50 EDT","volume":753,"amount":1151.6684706,"timestamp":1784897452994,"change":0.03,"changeRate":0.019868,"amplitude":0.088477},"postHourTrading":{"tag":"盘后","latestPrice":1.5,"preClose":1.48,"latestTime":"16:45 EDT","volume":619,"amount":915.0800181,"timestamp":1784925945176,"change":0.02,"changeRate":0.013514,"amplitude":0.02027},"volumeRatio":0.596433},"requestUrl":"/m/hq/s/MTVA/tweets","defaultTab":"tweets","newsList":[{"id":"2650184960","title":"Analyst Reaffirms Buy on MTVA as DA-1726 Data De-Risk Obesity and MASH Opportunity; Price Target Maintained at $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2650184960","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650184960?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:25","pubTimestamp":1783679120,"startTime":"0","endTime":"0","summary":"Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on MetaVia. The associated price target remains the same with $20.00. Andre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reaffirms-buy-on-mtva-as-da-1726-data-de-risk-obesity-and-mash-opportunity-price-target-maintained-at-20-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reaffirms-buy-on-mtva-as-da-1726-data-de-risk-obesity-and-mash-opportunity-price-target-maintained-at-20-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650181207","title":"Metavia Price Target Maintained with a $20.00/share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2650181207","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650181207?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:25","pubTimestamp":1783679100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings(END) Dow Jones NewswiresJuly 10, 2026 06:25 ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650924814","title":"Metavia Says All Active Patients Reach Highest Target Doses in Da-1726 Obesity Phase 1 Part 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2650924814","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650924814?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:33","pubTimestamp":1783600438,"startTime":"0","endTime":"0","summary":"MetaVia says all active patients reach highest target doses in DA-1726 obesity Phase 1 Part 3 studyMetaVia reached its highest target doses in all active patients in Part 3 of its Phase 1 obesity tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL8G7lMj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650921018","title":"Metavia - All Patients Reach Highest Target Doses of 48 Mg and 64 Mg in Phase 1 Part 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2650921018","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650921018?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:31","pubTimestamp":1783600260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUA5QWCSH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650792101","title":"Metavia - Topline Data from Phase 1 Part 3 Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650792101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650792101?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:31","pubTimestamp":1783600260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUA5QWCSH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650031921","title":"Metavia Announces Completion of Dose Titration in Phase 1 Part 3 Study of Da-1726 for the Treatment of Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2650031921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650031921?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:31","pubTimestamp":1783600260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUA5QWCSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644746547","title":"MetaVia CEO to join Life Sciences Virtual Investor Forum fireside chat on obesity, metabolic therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2644746547","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644746547?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:31","pubTimestamp":1781699499,"startTime":"0","endTime":"0","summary":"MetaVia will join the Life Sciences Virtual Investor Forum on June 24, 2026, featuring a fireside chat on its obesity and metabolic therapy pipeline.Hyung Heon Kim, president and CEO, is scheduled to participate at 10:30 a.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLFZvQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642249582","title":"Analysts Offer Insights on Healthcare Companies: MetaVia (MTVA) and Adlai Nortye Ltd. Sponsored ADR (ANL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642249582","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642249582?lang=en_us&edition=fundamental","pubTime":"2026-06-09 22:20","pubTimestamp":1781014855,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MetaVia (MTVA) and Adlai Nortye Ltd. Sponsored ADR (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-metavia-mtva-and-adlai-nortye-ltd-sponsored-adr-anl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-metavia-mtva-and-adlai-nortye-ltd-sponsored-adr-anl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4581","LABU","ANL","XBI","MTVA","LU0029874061.USD","ALN","BK4585","LU0128526141.USD","LU2133065610.SGD","XLV","BK4139","IE00BZ199S13.USD","BK4588","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642464941","title":"BRIEF-Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642464941","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642464941?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:02","pubTimestamp":1781002923,"startTime":"0","endTime":"0","summary":"BRIEF-Biostem Technologies Announces Appointment Of Three New Members To Its Board Of DirectorsJune 9 (Reuters) - Biostem Technologies Inc BSEM.PK:BIOSTEM TECHNOLOGIES ANNOUNCES APPOINTMENT OF THREE N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA1DXPTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BSEM","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642346463","title":"Biostem Technologies Announces Appointment of Three New Members to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642346463","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642346463?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:00","pubTimestamp":1781002801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA1DXPTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","MTVA","BSEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642359431","title":"Metavia - Stockholders Approve Reverse Stock Split at Ratio Between 1-for-5 and 1-for-22 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2642359431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642359431?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:03","pubTimestamp":1780948983,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nFWN42G0R9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431872","title":"MetaVia shareholders approved 200,000-share increase to equity incentive plan at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431872","media":"Reuters","labels":["executive","shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431872?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:01","pubTimestamp":1780948899,"startTime":"0","endTime":"0","summary":"Metavia held its virtual annual shareholder meeting on June 8, 2026.Shareholders passed an amendment to the 2022 equity incentive plan, increasing the share reserve by 200,000 shares; the increase is effective.Shareholders backed a charter amendment to allow a reverse stock split within a 1-for-5 to 1-for-22 range; the board has discretion on execution.Shareholders ratified BDO USA as independent auditor for fiscal 2026.Shareholders elected two Class I directors to three-year terms ending at the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Secur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLbzHyqH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"MetaVia shareholders approved 200,000-share increase to equity incentive plan at annual meeting","news_tag":"executive,shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641482383","title":"MetaVia presents data at ADA supporting DA-1726, vanoglipel","url":"https://stock-news.laohu8.com/highlight/detail?id=2641482383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641482383?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:48","pubTimestamp":1780922888,"startTime":"0","endTime":"0","summary":"MetaVia (MTVA) announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabet...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/metavia-presents-data-at-ada-supporting-da-1726-vanoglipel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/metavia-presents-data-at-ada-supporting-da-1726-vanoglipel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641845864","title":"MetaVia says Phase 1 trial shows DA-1726 cuts mean body weight up to 9.1% by Day 54","url":"https://stock-news.laohu8.com/highlight/detail?id=2641845864","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641845864?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:32","pubTimestamp":1780921930,"startTime":"0","endTime":"0","summary":"Metavia disclosed late-breaking ADA 2026 results already presented for DA-1726, its once-weekly obesity candidate, showing continued weight loss without an early plateau.The Phase 1 update supported the program’s safety and tolerability profile, underpinning plans to keep pushing into higher-dose testing.Management guided to Phase 1 Part 3 titration readouts in Q4 2026, a key near-term catalyst for dosing strategy and durability.Preclinical ADA posters also indicated vanoglipel could strengthen weight-loss and metabolic effects when paired with established therapies, supporting combination positioning.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL4v603F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157287","title":"MetaVia to present at Emerging Growth Conference on obesity, metabolic therapy pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157287","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157287?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:33","pubTimestamp":1780576408,"startTime":"0","endTime":"0","summary":"MetaVia will present a pipeline update at the Emerging Growth Conference on June 11, 2026 at 3:25 pm ET.Hyung Heon Kim, president and CEO, will present alongside CFO Marshall H. Woodworth.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL1jv6VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638150071","title":"MetaVia says Phase 1 trial shows DA-1726 cuts mean body weight up to 9.1% at 48 mg dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2638150071","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638150071?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:33","pubTimestamp":1779885207,"startTime":"0","endTime":"0","summary":"MetaVia presented higher-dose Phase 1 results for obesity drug candidate DA-1726 at EASL 2026 on May 27.The study showed meaningful, continuing weight loss with no sign of an early plateau during follow-up.Safety profile looked manageable, with mostly mild-to-moderate gastrointestinal side effects and no treatment-related dropouts reported.Exploratory liver scans suggested early improvements consistent with potential use in obesity-related liver disease, including MASH.Ongoing Phase 1 titration studies are testing longer treatment and higher-dose strategies to support next-stage development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL185sW6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638002545","title":"Metavia Presents Higher-Dose Phase 1 Results for Da-1726 at Easl Congress 2026, Supporting Potential in Obesity and Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2638002545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638002545?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:31","pubTimestamp":1779885061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA3KYGH8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637631645","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2637631645","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637631645?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:18","pubTimestamp":1779448694,"startTime":"0","endTime":"0","summary":"PicoCELA  shares were up 172% in Friday premarket activity, extending Thursday's 60% rally.Leifras  stock was 113% higher after the company agreed to acquire Tokai Sports.Akari Therapeutics  shares were up 64% after the company reported positive preclinical data for its AKTX-101 investigational drug candidate.MetaVia  stock was 40% higher following a muted session.HCW Biologics  shares were up 25% after the company priced a private securities offering.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LFS.AU","BK4148","LFS","AKTS","MTVA","BK4020","AKTX","BK4139","BK4539","BK4007","PCLA","BK4204","BK7093","HCWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637684352","title":"Why MetaVia Stock Is Falling On Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2637684352","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637684352?lang=en_us&edition=fundamental","pubTime":"2026-05-22 02:30","pubTimestamp":1779388200,"startTime":"0","endTime":"0","summary":"MetaVia Inc. (NASDAQ: MTVA) shares drop over 10% on Thursday due to profit-taking despite announcing peer-reviewed data supporting its anti-fibrotic MASH drug candidate.","market":"sh","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=260,dpr=2,format=auto,quality=85/files/images/story/2026/05/21/Financial-Market-Crash-Concept-With-Red-.jpeg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=260,dpr=2,format=auto,quality=85/files/images/story/2026/05/21/Financial-Market-Crash-Concept-With-Red-.jpeg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/05/52728981/why-metavia-stock-is-falling-on-thursday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/05/52728981/why-metavia-stock-is-falling-on-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636844503","title":"MetaVia cites preclinical study showing vanoglipel reduces liver fibrosis in MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2636844503","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636844503?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:02","pubTimestamp":1779278560,"startTime":"0","endTime":"0","summary":"MetaVia highlighted a newly published peer-reviewed preclinical study supporting an anti-fibrotic effect for its GPR119 agonist vanoglipel in metabolic liver disease.Results were already presented via the journal publication, with findings indicating reduced liver scarring signals in laboratory models.The readout adds mechanistic support to a previously completed Phase 2a study in presumed MASH, which showed improvements in liver injury and fibrosis markers versus placebo.The company positioned the data as strengthening the case for vanoglipel as a potential standalone therapy or a combination option in MASH with fibrosis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL2qHcCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.metaviatx.com","stockEarnings":[{"period":"1week","weight":-0.1611},{"period":"1month","weight":-0.0195},{"period":"3month","weight":-0.0321},{"period":"6month","weight":-0.4664},{"period":"1year","weight":-0.8091},{"period":"ytd","weight":-0.8207}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.034},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1639},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.000503},{"month":2,"riseRate":0.3,"avgChangeRate":0.007282},{"month":3,"riseRate":0.5,"avgChangeRate":-0.031121},{"month":4,"riseRate":0.4,"avgChangeRate":-0.109498},{"month":5,"riseRate":0.3,"avgChangeRate":-0.001142},{"month":6,"riseRate":0.5,"avgChangeRate":0.031858},{"month":7,"riseRate":0.3,"avgChangeRate":-0.018246},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.189997},{"month":9,"riseRate":0.4,"avgChangeRate":0.065402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.186131},{"month":11,"riseRate":0.3,"avgChangeRate":-0.112358},{"month":12,"riseRate":0.1,"avgChangeRate":-0.160075}],"exchange":"NASDAQ","name":"MetaVia Inc","nameEN":"MetaVia Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MetaVia Inc(MTVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MetaVia Inc,MTVA,MetaVia Inc股票,MetaVia Inc股票老虎,MetaVia Inc股票老虎国际,MetaVia Inc行情,MetaVia Inc股票行情,MetaVia Inc股价,MetaVia Inc股市,MetaVia Inc股票价格,MetaVia Inc股票交易,MetaVia Inc股票购买,MetaVia Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MetaVia Inc(MTVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction